A systematic review of medical treatments for children with autism spectrum disorders

Pediatrics

Volumn 127, Issue 5, 2011, Pages

  McPheeters, Melissa L ^a,b   Warren, Zachary ^a,b   Sathe, Nila ^a   Bruzek, Jennifer L ^a   Krishnaswami, Shanthi ^a   Jerome, Rebecca N ^b   Veenstra VanderWeele, Jeremy ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Aripiprazole; Autism spectrum disorders; Citalopram; Fluoxetine; Psychostimulants; Risperidone; Serotonin reuptake inhibitors

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CYPROHEPTADINE; DEXAMPHETAMINE; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; METHYLPHENIDATE; PLACEBO; RISPERIDONE;

AGITATION; ANXIETY; APPETITE DISORDER; AUTISM; CHILD; CLINICAL ASSESSMENT; DEPRESSION; DIARRHEA; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY SKIN; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; IRRITABILITY; META ANALYSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PRURITUS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGIDITY; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SLEEP; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR;

ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; FLUOXETINE; HUMANS; MALE; PATIENT COMPLIANCE; PIPERAZINES; PROGNOSIS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79955491854     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-0427     Document Type: Review

References (54)

1. Autism and Developmental Disabilities Monitoring Network. Prevalence of the Autism Spectrum Disorders (ASDs) in Multiple Areas of the United States, 2004 and 2006. Atlanta, GA: Centers for Disease Control and Prevention; 2009. Available at: www.cdc.gov/ncbddd/ autism/states/ADDMCommunityReport2009. pdf. Accessed March 9, 2011
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000
3. Zwaigenbaum L, Bryson S, Lord C, et al. Clinical assessment and management of toddlers with suspected autism spectrum disorder: insights from studies of high-risk infants. Pediatrics. 2009;123(5):1383-1391
4. Myers SM, Johnson CP; American Academy of Pediatrics, Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics. 2007; 120(5):1162-1182
5. Myers SM. Management of autism spectrum disorders in primary care. Pediatr Ann. 2009;38(1):42-49
6. National Autism Center. National Standards Report. Randolph, MA: National Autism Center; 2009. Available at: www.nationalautismcenter. org/pdf/NAC Standards Report.pdf. Accessed March 9, 2011
7. National Research Council, Committee on Educational Interventions for Children With Autism. Educating Children With Autism. Washington, DC; National Academies Press; 2001. Available at: http://books.nap.edu/ catalog.php?record- id=10017. Accessed March 9, 2011
8. Warren Z, Veenstra-VanderWeele J, Stone W, Bruzek JL, Nahmias AS, Foss-Feig JH, et al. Therapies for Children With Autism Spectrum Disorders. Comparative Effectiveness Review 26. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract 290-02-HHSA-290-2007-10065-I.) AHRQ Publication 11-EHC035-EF. Rockville, MD: Agency for Healthcare Research and Q u a l i t y ; 2 0 0 7 A v a i l a b l e a t : www. effectivehealthcare.ahrq.gov/reports/final. cfm. Accessed March 2011
9. Krishnaswami S, McPheeters ML, Veenstra- VanderWeele J. A systematic review of secretin for children with autism spectrum disorders. Pediatrics. 2011;127(5). Available at: www.pediatrics.org/cgi/content/ full/127/5/eXXX
10. Lord C, Risi S, Lambrecht L, et al. The Autism Diagnostic Observation Schedule-Generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000; 30(3):205-223
11. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659-685 (Pubitemid 24309810)
12. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the effective healthcare program. J Clin Epidemiol. 2010;63(5): 513-523
13. Aman MG, Hollway JA, McDougle CJ, et al. Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol. 2008;18(3): 227-236
14. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005; 15(6):869-884 (Pubitemid 43042978)
15. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162(7): 1361-1369
16. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142-1148 (Pubitemid 40770697)
17. Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry. 2004;161(6):1125-1127 (Pubitemid 38736004)
18. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321 (Pubitemid 34815353)
19. Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003;42(12): 1443-1450 (Pubitemid 39585974)
20. Williams SK, Scahill L, Vitiello B, et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry. 2006;45(4):431-439 (Pubitemid 43675548)
21. Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61(4): 545-550 (Pubitemid 46185331)
22. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37(2): 367-373
23. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5). Available at: www.pediatrics.org/cgi/content/full/114/ 5/e634
24. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebocontrolled, double-blind study. J Child Neurol. 2006;21(6):450-455 (Pubitemid 44069792)
25. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry. 2003;64(9):1039-1047 (Pubitemid 37158249)
26. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119
27. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540
28. Akhondzadeh S, Erfani S, Mohammadi MR, et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebocontrolled trial. J Clin Pharm Ther. 2004; 29(2):145-150 (Pubitemid 38482479)
29. Correia CT, Almeida JP, Santos PE, et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010;10(5):418-430
30. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30(3):582-589 (Pubitemid 40271160)
31. DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol. 2002;44(10): 652-659 (Pubitemid 35230025)
32. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583-590
33. Owley T, Brune CW, Salt J, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 2010;3(1): 1-7
34. Henry CA, Steingard R, Venter J, Guptill J, Halpern EF, Bauman M. Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review. J Child Adolesc Psychopharmacol. 2006;16(1-2):187-195
35. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266-1274
36. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61(4): 538-544 (Pubitemid 46185343)
37. Jahromi LB, Kasari CL, McCracken JT, et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord. 2009;39(3):395-404
38. Nickels K, Katusic SK, Colligan RC, Weaver AL, Voigt RG, Barbaresi WJ. Stimulant medication treatment of target behaviors in children with autism: a populationbased study. J Dev Behav Pediatr. 2008; 29(2):75-81 (Pubitemid 351535878)
39. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14(2):233-241 (Pubitemid 38988789)
40. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004; 14(1):49-56 (Pubitemid 38525953)
41. Scahill L, McDougle CJ, Williams SK, et al. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(9):1114-1123 (Pubitemid 44343067)
42. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;19(2): 227-239 (Pubitemid 19176531)
43. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry. 1984;141(10): 1195-1202 (Pubitemid 14011490)
44. Aman MG, Lam KS, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol. 2005;15(1):116-126 (Pubitemid 40365921)
45. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33(5):527-534 (Pubitemid 37351601)
46. Esbensen AJ, Greenberg JS, Seltzer MM, Aman MG. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord. 2009;39(9): 1339-1349
47. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61(4):551-553 (Pubitemid 46185334)
48. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-1205 (Pubitemid 44465640)
49. Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, doubleblind, controlled trial. BMC Pediatr. 2009; 9:21
50. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010; 67(7):692-694
51. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007; 191(1):141-147 (Pubitemid 46294942)
52. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753-2766
53. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292(16):1969-1976
54. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7): 807-820 (Pubitemid 39079667)